H₁ antihistamines: patent highlights 2000 – 2005

Author： Fonquerna Silvia Miralpeix Montserrat

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.16, Iss.2, 2006-02, pp. : 109-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Since the introduction of the first H₁ antihistamine in 1945, much progress has been made in eliminating troublesome side effects. Early efforts were directed at improving selectivity and avoiding sedative properties, and later at preventing the non-mechanism-related cardiotoxicity observed in some of the second-generation H₁ antihistamines. As the H₁ antihistamines are still the first choice therapy against allergy symptoms, there remains an opportunity to obtain compounds with an improved and differentiated pharmacological and therapeutic profile. A patent literature review comprising the years 2000 – 2005 shows a reduction in the number of new chemical entities as H₁ antihistamines and a growing interest in dual H₁-X compounds. With the introduction of dual H₁-H₃ and H₁-CCR3 antagonists, a new direction of research has emerged that offers the potential of discovering a superior H₁ antihistamine with anti-inflammatory properties able to deal with the inflammation and nasal congestion associated with allergic diseases.